Table 4.
Treatment | Disease base | 3d | 7d | 14d | 21d | 30d | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
Disease index | Control effect | Disease index | Control effect | Disease index | Control effect | Disease index | Control effect | Disease index | Control effect | ||
CK | 16.84ab ± 2.03 | 29.02d ± 2.54 | – | 33.81c ± 2.74 | – | 42.11d ± 1.14 | – | 54.14d ± 1.93 | – | 63.72d ± 2.47 | – |
YN201732M1 | 15.41a ± 1.94 | 18.17c ± 2.22 | 37.39 | 25.02b ± 2.09 | 24.59 | 35.19c ± 1.87 | 16.43 | 46.79c ± 2.33 | 13.58 | 59.21cd ± 1.75 | 7.08 |
YN201732M2 | 15.99a ± 0.87 | 11.14ab ± 1.44 | 61.61 | 10.73a ± 0.99 | 67.66 | 20.64b ± 1.97 | 50.99 | 34.34b ± 2.74 | 36.57 | 54.99bc ± 3.08 | 13.7 |
YN201732M3 | 17.41ab ± 2.79 | 13.10b ± 1.68 | 54.86 | 11.46a ± 0.64 | 65.46 | 21.32b ± 2.49 | 49.37 | 32.59b ± 3.31 | 39.8 | 56.07bc ± 3.32 | 12.01 |
YN201732 | 18.81b ± 1.26 | 9.08a ± 1.10 | 68.71 | 9.34a ± 2.75 | 71.85 | 14.60a ± 0.98 | 65.33 | 29.24b ± 1.59 | 45.99 | 52.84b ± 2.59 | 17.07 |
Azoxystrobin 50% WG | 19.02b ± 3.03 | 12.76b ± 1.33 | 56.03 | 12.58a ± 1.05 | 62.09 | 10.68a ± 1.43 | 74.64 | 9.17a ± 0.79 | 83.06 | 11.85a ± 2.68 | 81.4 |
Different letters indicate that the differences are significant (P < 0.05) using Duncan’s multiple range test.